August 28, 2015
Five Star Friday – Reuters Health, Wall Street Journal, Vox.com get top grades
Just a quick note, but we want to draw attention to the fact that we published three top-rated five-star story reviews this week. They were:
- Reuters Health’s “An aspirin a day – for years – may keep colon cancer away.” Excerpt of our review: “A strong story that describes in clear terms the findings as well as the strengths and weaknesses of this study. It covered potential biases that could not be controlled, mentioned harms, and was overall very cautious.”
- The Wall Street Journal’s “Heart Drug Linked to Extra Years for Cancer Patients.” Excerpt from our review: “This Wall Street Journal article nicely summarizes the findings of a retrospective study of 1,400 cases of women with ovarian cancer; some of whom had been prescribed beta-blockers for high blood pressure and appeared to have better outcomes than those not taking beta-blockers. It hits on nearly all of our criteria, and was more thorough and balanced than an MD Anderson news release that initially announced the findings to the world.”
- A Vox.com story, “Should you take Tylenol, Advil, or aspirin for pain? Here’s what the evidence says.” Excerpt of our review:
“In this installment of “Dear Julia,” Vox health reporter Julia Belluz takes on a reader question about pain medications. The reader wants to know which over-the-counter (OTC) pain reliever is the best for treating pain – Tylenol, Advil or aspirin. The story presents evidence from high-quality studies and opinions from three pain experts. The story carefully explains that it’s not appropriate to state unequivocally that one beats the other because it’s not a one-size-fits all situation. In general, though, ibuprofen (name brand Advil) is more effective and safer than acetaminophen (Tylenol) and aspirin in beating minor pain.
The “Dear Julia” column, which debuted earlier this month, promises to answer “everyday health questions on anything from the science of hangovers to the mysteries of back pain.” The column is off to an auspicious start, and we look forward to more of its practical, evidence-based responses.”